Loading…
Loading…
RNUGF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for RNUGF and 80,000+ other tickers.
See exactly how RNUGF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RNUGF and 80,000+ other tickers.
ReNeuron Group plc is a UK-based biotechnology firm dedicated to the discovery, advancement, and eventual market launch of cutting-edge cell-based medical treatments. Their current pipeline features a CTX stem cell therapy, designed to improve outcomes for individuals suffering from stroke-related disabilities. Additionally, the company is progressing with its human retinal progenitor cell therapy, which is currently in Phase 2 clinical trials, aiming to address retinitis pigmentosa, a condition leading to blindness. Beyond these primary therapies, ReNeuron is also developing CTX-derived…
ReNeuron Group PLC (AIM:RENE, OTC:RNUGF) said it would delist from AIM after it called time on City fundraising efforts to focus on the ongoing administration process. In an update, the company said it was not in the best interests of existing shareholders to pursue a "highly dilutive" equity fundraise, given the limited funds identified and the terms offered by potential investors.
ReNeuron Group PLC (AIM:RENE, OTC:RNUGF) said it is seeking potential new investors to enable the company to trade as a going concern following an exit from administration. However, there is a discrepancy between the amount it can pay existing creditors and the amount they are seeking, sad the statement.
ReNeuron Group PLC (AIM:RENE, OTC:RNUGF), the stem cell group placed into administration in March, said it is exploring an equity fundraiser to recapitalise the business. In an update, it was stressed that this was just one potential option being mulled alongside the possible sale of its subsidiary, or piecemeal asset disposal.
ReNeuron is to present in vivo data exemplifying the cellular and tissue targeting capabilities and highlighting the significant advantages of its CustomEX drug delivery platform at Cell 2023 in London. Data to be presented shows the significant improvement in targeting and delivery of payloads that can be achieved through the careful selection of specific exosomes from different cell sources, said the company.
ReNeuron said it had taken an important step forward with plans to differentiate its exosome platform by generating in vivo data highlighting its distinct organ and cellular targeting capabilities. Iain Ross, executive chairman, said: "On the basis of this data the company will now look to broaden its capabilities and, in liaison with partners and collaborators, focus on the functional delivery of specific payloads”s.